Fig. 6
From: p85S6K sustains synaptic GluA1 to ameliorate cognitive deficits in Alzheimer’s disease
Overexpression of p85S6K ameliorates cognitive decline and spine deficits in AD mice. a–f Morris water maze was carried out to assess spatial learning and memory. a Latency of WT and APP/PS1 mice to locate the hidden platform in the training period. F(1, 39) = 97.50, P < 0.0001 for genotype effect, F(1, 39) = 14.48, P = 0.0005 for p85S6K overexpression effect. b The average speed of WT and APP/PS1 mice in the training period. c The time spent in the target quadrant in the probe test. F(1, 39) = 6.731, P = 0.0133 for genotype effect, F(1, 39) = 9.915, P = 0.0013 for p85S6K overexpression effect. d The average speed of WT and APP/PS1 mice in the probe test. e The number of platform crossings of WT and APP/PS1 mice in the probe test. F(1, 39) = 4.522, P = 0.0398 for genotype effect, F(1, 39) = 7.984, P = 0.0074 for p85S6K overexpression effect. f Representative swimming trajectories in the probe test. The green circle represented the location of the hidden platform. n = 11 mice for WT-Ctl, WT-p85S6K OE, and APP/PS1-Ctl groups; n = 10 for the APP/PS1-p85S6K OE group. g, h The expression levels of p-Ser845 GluA1 and total GluA1 in the hippocampus after injection of AAVs expressing p85S6K or control AAVs. n = 5 mice per group. Left panel in h: F(1, 16) = 4.731, P = 0.0450 for genotype effect, F(1, 16) = 5.540, P = 0.0317 for p85S6K overexpression effect; right panel in h: F(1, 16) = 6.906, P = 0.0183 for genotype effect, F(1, 16) = 0.1139, P = 0.7401 for p85S6K overexpression effect. i, j Spine density in the hippocampus of WT and APP/PS1 mice after overexpression of p85S6K. Scale bars, 200 μm (left panel) and 1 μm (right panel). n = 9 slices from 4 mice per group. F(1, 32) = 14.97, P = 0.0005 for genotype effect, F(1, 32) = 16.22, P = 0.0003 for p85S6K overexpression effect. Data are presented as mean ± SEM. Three-way ANOVA (a, b) or two-way ANOVA (c, d, e, h, j) followed by Tukey's or Bonferroni's test. *P < 0.05, **P < 0.01, ****P < 0.0001. Ctl control, i.e., mice injected with control AAVs. OE overexpression